Our Programs

Our pipeline includes four clinical-stage drug candidates targeting different mechanisms critical to overcoming cancer progression and drug resistance:

• Zandelisib, an oral PI3K delta inhibitor;
• Voruciclib, an oral CDK inhibitor; and
• ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.
• Pracinostat, an oral HDAC inhibitor;

Our portfolio is built around drug candidates with validated targets and is designed to develop medicines that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other medicines.

Zandelisib Oral P13K Delta Inhibitor
INDICATION	COMBINATION	PHASE1/1B	PHASE2	PHASE3	COMMERCIAL RIGHTS
Follicular Lymphoma Relapsed/refractory	Monotherapy	TIDAL: Accelerated Approval Trial 1			U.S. co-promote; ex- U.S. Kiyowa Kirin exclusive rights
B-Cell Malignancies Relapsed/refractory	Monotherapy Rituxan® (rituximab) Zanubrutinib2	60% 60% Clinical Collaboration

Voruciclib CDK Inhibitor
INDICATION	COMBINATION	PHASE1/1B	PHASE2	PHASE3	COMMERCIAL RIGHTS
B-Cell Malignancies & AML Relapsed/refractory	Monotherapy Venclexta® (venetoclax)3	60% 60%

ME-344 Mitochondrial Inhibitor
INDICATION	COMBINATION	PHASE1/1B	PHASE2	PHASE3	COMMERCIAL RIGHTS
HER2-Breast Cancer Treatment-naive, early stage	Avastin® (bevacizumab)4	60%

Pracinostat HDAC Inhibitor
INDICATION	COMBINATION	PHASE1/1B	PHASE2	PHASE3	COMMERCIAL RIGHTS
Myelodysplastic Syndrome Treatment-naive	Vidaza® (azacitidine)	60%

¹ Phase 2 study to support an accelerated approval marketing application with FDA
² Study arm initiated under clinical collaboration with BeiGene, Ltd.
³ Initiation of clinical studies is subject to opening of a new Investigational New Drug Application with FDA
⁴ Investigator-initiated trial